StreetInsider.com News Articles

Ernexa Therapeutics completes manufacturing milestones for ERNA-101

Wed, 27 May 2026 08:11:51 -0400

Ernexa Therapeutics (NASDAQ: ERNA) completed process development activities for its ERNA-101 cell therapy and transitioned into Good Manufacturing Practice manufacturing in preparation for clinical development. The company announced these milestones as it prepares for an Investigational New Drug submission planned for the third quarter of 2026.

The Cambridge, Massachusetts-based biotechnology company said technology transfer activities for ERNA-101 are underway, supporting the planned IND submission timeline. ERNA-101 is designed to activate and regulate immune system responses to recognize and attack cancer cells.

"Completing process development and advancing into GMP manufacturing are critical steps toward IND clearance and the launch of our first-in-human clinical

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

Wed, 27 May 2026 08:11:00 -0400

Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced significant progress in the development of ERNA-101, the company’s lead therapeutic candidate, achieving multiple critical milestones that position the program for a planned Investigational New Drug (IND) submission in the third quarter of 2026 and the anticipated initiation of its first-in-human clinical study.

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

Wed, 27 May 2026 08:11:00 -0400

Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

Wed, 27 May 2026 08:11:00 -0400

Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

Wed, 27 May 2026 08:11:00 -0400

Company remains on track for anticipated IND filing in Q3 2026, marking a transformative step toward becoming a clinical-stage biotechnology company

Form SCHEDULE 13G/A Ernexa Therapeutics Inc. Filed by: CLEAR STREET LLC

Wed, 20 May 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260520/26529201.html

Form SCHEDULE 13G/A Ernexa Therapeutics Inc. Filed by: CLEAR STREET LLC

Wed, 20 May 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260520/26529201.html

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Wed, 20 May 2026 08:31:00 -0400

Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies

Segment also discusses evolving treatment landscape, immunologically “cold” tumors and the future potential of off-the-shelf cell therapy approaches

Access the segment here

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Wed, 20 May 2026 08:31:00 -0400

Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies

Segment also discusses evolving treatment landscape, immunologically “cold” tumors and the future potential of off-the-shelf cell therapy approaches

Access the segment here

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Wed, 20 May 2026 08:31:00 -0400

Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies

Segment also discusses evolving treatment landscape, immunologically “cold” tumors and the future potential of off-the-shelf cell therapy approaches

Access the segment here

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Wed, 20 May 2026 08:31:00 -0400

Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies

Segment also discusses evolving treatment landscape, immunologically “cold” tumors and the future potential of off-the-shelf cell therapy approaches

Access the segment here